(Q3 Un-audited): EPS was Tk. (0.09) for January-March 2026 as against Tk. (0.10) for January-March 2025; EPS was Tk. (0.23) for July 2025-March 2026 as against Tk. (0.24) for July 2024-March 2025. NOCFPS was Tk. (0.01) for July 2025-March 2026 as against Tk. (0.00) for July 2024-March 2025. NAV per share was Tk. 6.64 as on March 31, 2026 and Tk. 6.87 as on June 30, 2025.

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 2:30 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.

(Q2 Un-audited): EPS was Tk. (0.06) for October-December 2025 as against Tk. (0.14) for October-December 2024; EPS was Tk. (0.14) for July-December 2025 as against Tk. (0.16) for July-December 2024. NOCFPS was Tk. 0.01 for July-December 2025 as against Tk. 0.00 for July-December 2024. NAV per share was Tk. 6.74 as on December 31, 2025 and Tk. 6.87 as on June 30, 2025.

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 28, 2026 at 3:30 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.

The auditor of the company has given Adverse Opinion in the audited financial statements for the year ended on 30 June 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/141.%20Central%20Pharmaceuticals%20Ltd_.pdf